Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics
GET POWR RATINGS... FREE!
RYTM POWR Grades
- RYTM scores best on the Growth dimension, with a Growth rank ahead of 50.53% of US stocks.
- The strongest trend for RYTM is in Quality, which has been heading up over the past 161 days.
- RYTM ranks lowest in Quality; there it ranks in the 6th percentile.
RYTM Stock Summary
- Rhythm Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 6.44% of US listed stocks.
- RYTM's price/sales ratio is 304.54; that's higher than the P/S ratio of 98.72% of US stocks.
- As for revenue growth, note that RYTM's revenue has grown 3,720% over the past 12 months; that beats the revenue growth of 99.66% of US companies in our set.
- Stocks that are quantitatively similar to RYTM, based on their financial statements, market capitalization, and price volatility, are ETON, OVID, TGTX, LBRDA, and SGBX.
- RYTM's SEC filings can be seen here. And to visit Rhythm Pharmaceuticals Inc's official web site, go to www.rhythmtx.com.
RYTM Valuation Summary
- RYTM's price/sales ratio is 2114.9; this is 18533.48% higher than that of the median Healthcare stock.
- RYTM's EV/EBIT ratio has moved up 15.3 over the prior 48 months.
- RYTM's price/sales ratio has moved NA NA over the prior 48 months.
Below are key valuation metrics over time for RYTM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RYTM | 2021-08-31 | 2114.9 | 1.9 | -10.8 | -13.5 |
| RYTM | 2021-08-30 | 2066.0 | 1.8 | -10.6 | -13.2 |
| RYTM | 2021-08-27 | 2108.4 | 1.9 | -10.8 | -13.5 |
| RYTM | 2021-08-26 | 1984.8 | 1.7 | -10.2 | -12.6 |
| RYTM | 2021-08-25 | 2028.5 | 1.8 | -10.4 | -12.9 |
| RYTM | 2021-08-24 | 2017.2 | 1.8 | -10.3 | -12.8 |
RYTM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RYTM has a Quality Grade of F, ranking ahead of 2.46% of graded US stocks.
- RYTM's asset turnover comes in at 0.004 -- ranking 418th of 681 Pharmaceutical Products stocks.
- EVOK, ATRA, and EVFM are the stocks whose asset turnover ratios are most correlated with RYTM.
The table below shows RYTM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.004 | 0.728 | -0.232 |
| 2021-06-30 | 0.001 | 0.544 | -0.211 |
| 2021-03-31 | 0.000 | 0.886 | -0.196 |
| 2020-12-31 | 0.000 | NA | -0.922 |
| 2020-09-30 | 0.000 | NA | -0.718 |
| 2020-06-30 | 0.000 | NA | -0.784 |
RYTM Price Target
For more insight on analysts targets of RYTM, see our RYTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $36.67 | Average Broker Recommendation | 1.71 (Moderate Buy) |
RYTM Stock Price Chart Interactive Chart >
RYTM Price/Volume Stats
| Current price | $7.59 | 52-week high | $43.26 |
| Prev. close | $7.96 | 52-week low | $7.55 |
| Day low | $7.55 | Volume | 265,369 |
| Day high | $8.45 | Avg. volume | 305,851 |
| 50-day MA | $10.29 | Dividend yield | N/A |
| 200-day MA | $15.18 | Market Cap | 381.53M |
Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.
Latest RYTM News From Around the Web
Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.
Rhythm Pharmaceuticals: PDUFA Ahead, But Commercialization Concerns RemainNo summary available. |
Dosing underway in Rhythm Pharma''s setmelanotide trial for rare genetic disease of obesityRhythm Pharmaceuticals < |
Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity ---- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused by variants in one of 31 pre-identified genes ---- First patient also dosed in Phase 3 switch trial evaluating a weekly formulation of setmelanotide -- BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to tra |
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gapped up prior to trading on Monday . The stock had previously closed at $9.64, but opened at $10.16. Rhythm Pharmaceuticals shares last traded at $10.16, with a volume of 6 shares trading hands. A number of research analysts have commented on the stock. The Goldman Sachs Group upgraded shares of [] The post Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64 appeared first on ETF Daily News . |
Zacks: Analysts Anticipate Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to Announce -$1.00 EPSWall Street analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to announce earnings per share (EPS) of ($1.00) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Rhythm Pharmaceuticals earnings, with estimates ranging from ($1.08) to ($0.91). Rhythm Pharmaceuticals reported earnings per share of ($0.79) during the same quarter last year, [] |
RYTM Price Returns
| 1-mo | -33.94% |
| 3-mo | -30.87% |
| 6-mo | -62.09% |
| 1-year | -78.38% |
| 3-year | -74.73% |
| 5-year | N/A |
| YTD | -23.95% |
| 2021 | -66.43% |
| 2020 | 29.49% |
| 2019 | -14.58% |
| 2018 | -7.50% |
| 2017 | N/A |
Loading social stream, please wait...